



8th February, 2019

BSE LIMITED Phiroze Jeejeebhoy Towers Dalal Street, Mumbai – 400001 Scrip Code: BSE – AJANTPHARM 532331	National Stock Exchange of India, Exchange Plaza, 5 th Floor, Plot no. C/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051 Scrip Code: NSE AJANTPHARM EQ
--	--

Sub.: Compliance Under Regulation 47 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 ('Listing Regulations')

Dear Sir/Madam,

Pursuant to Regulation 47 of the Listing Regulations, please find enclosed copies of financial results of the Company for the quarter ended 31st December, 2018 published in the following newspapers on 1st February 2019:

1. Mumbai edition of Economic Times and
2. Mumbai edition of Maharashtra Times;

This is for your information and record.

Yours faithfully,

GAURANG SHAH

AVP - Legal & Company Secretary

Encl.: a/a



ajanta pharma limited

Regd. Office: 'Ajanta House', Charkop, Kandivli (W), Mumbai-67,

Phone - +91-22-66061000, Fax - +91-22-66061200

CIN - L24230MH1979PLC022059,

Email - info@ajantapharma.com, Website - www.ajantapharma.com

Extract of Unaudited Consolidated Financial Results for the quarter and nine months ended 31 December 2018

₹ in Crore					
	Particulars	Quarter ended 31-12-2018	Nine month ended 31-12-2018	Quarter ended 31-12-2017	Year ended 31-03-2018
1	Total Income from Operations	485.11	1,540.21	587.05	2,130.86
2	Net Profit for the period before tax (before and after exceptional and/or extraordinary items)	92.96	405.08	197.53	622.55
3	Net Profit for the period after tax (after exceptional and/or extraordinary items)	66.90	298.08	147.47	468.64
4	Total Comprehensive Income for the period (comprising profit for the period after tax and other comprehensive income after tax)	66.71	294.91	146.69	472.34
5	Equity Share Capital	17.69	17.69	17.69	17.69
6	Reserve (excluding Revaluation Reserve) as shown in audited balance sheet of 31 March 2018				2,023.68
7	Earnings Per Share (FV of ₹ 2/- each)				
	(a) Basic - in ₹	7.60	33.87	16.76	53.26
	(b) Diluted - in ₹	7.60	33.86	16.75	53.25

Key information on Standalone Financial Results :

Particulars	Quarter ended 31-12-18	Nine month ended 31-12-18	Quarter ended 31-12-17	Year ended 31-03-18
Total Income from Operations	451.85	1,359.09	500.78	1,830.45
Profit Before Tax	125.70	461.04	203.83	562.44
Profit After Tax	95.47	350.39	164.59	427.52
Total Comprehensive Income	95.15	349.42	164.56	426.22

Notes:

- The above financial results have been reviewed by Audit Committee and thereafter approved by the Board of Directors at their meeting held on 30 January 2019.
- Board of Directors have approved buyback proposal, for purchase by the Company of up to 7,69,230 shares of ₹2 each (representing 0.87% of total paid-up equity capital) from the shareholders of the Company on a proportionate basis by way of a tender offer at a price of ₹1,300 per equity share for an aggregate amount not exceeding ₹100 crores in accordance with the provisions of the Companies Act, 2013 and the SEBI (Buy Back of Securities) Regulations, 2018.
- The above is an extract of the detailed format of Quarter and Nine months Financial Results filed with Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the standalone and consolidated financial results for the quarter and nine months ended 31 December 2018 are available on stock exchange websites www.nseindia.com and www.bseindia.com and on Company's website www.ajantapharma.com.

By order of the Board
For Ajanta Pharma Ltd.

Yogesh M. Agrawal
Managing Director

Mumbai, 30 January 2019



ajanta pharma limited

Regd. Office: 'Ajanta House', Charkop, Kandivli (W), Mumbai-67,

Phone - +91-22-66061000, Fax - +91-22-66061200

CIN - L24230MH1979PLC022059,

Email - info@ajantapharma.com, Website - www.ajantapharma.com

Extract of Unaudited Consolidated Financial Results for the quarter and nine months ended 31 December 2018

					₹ in Crore
	Particulars	Quarter ended 31-12-2018	Nine month ended 31-12-2018	Quarter ended 31-12-2017	Year ended 31-03-2018
1	Total Income from Operations	485.11	1,540.21	587.05	2,130.86
2	Net Profit for the period before tax (before and after exceptional and/or extraordinary items)	92.96	405.08	197.53	622.55
3	Net Profit for the period after tax (after exceptional and/or extraordinary items)	66.90	298.08	147.47	468.64
4	Total Comprehensive Income for the period (comprising profit for the period after tax and other comprehensive income after tax)	66.71	294.91	146.69	472.34
5	Equity Share Capital	17.69	17.69	17.69	17.69
6	Reserve (excluding Revaluation Reserve) as shown in audited balance sheet of 31 March 2018				2,023.68
7	Earnings Per Share (FV of ₹ 2/- each)				
	(a) Basic - in ₹	7.60	33.87	16.76	53.26
	(b) Diluted - in ₹	7.60	33.86	16.75	53.25

Key information on Standalone Financial Results :

Particulars	Quarter ended 31-12-18	Nine month ended 31-12-18	Quarter ended 31-12-17	Year ended 31-03-18
Total Income from Operations	451.85	1,359.09	500.78	1,830.45
Profit Before Tax	125.70	461.04	203.83	562.44
Profit After Tax	95.47	350.39	164.59	427.52
Total Comprehensive Income	95.15	349.42	164.56	426.22

Notes:

- The above financial results have been reviewed by Audit Committee and thereafter approved by the Board of Directors at their meeting held on 30 January 2019.
- Board of Directors have approved buyback proposal, for purchase by the Company of up to 7,69,230 shares of ₹2 each (representing 0.87% of total paid-up equity capital) from the shareholders of the Company on a proportionate basis by way of a tender offer at a price of ₹1,300 per equity share for an aggregate amount not exceeding ₹100 crores in accordance with the provisions of the Companies Act, 2013 and the SEBI (Buy Back of Securities) Regulations, 2018.
- The above is an extract of the detailed format of Quarter and Nine months Financial Results filed with Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the standalone and consolidated financial results for the quarter and nine months ended 31 December 2018 are available on stock exchange websites www.nseindia.com and www.bseindia.com and on Company's website www.ajantapharma.com.

By order of the Board
For Ajanta Pharma Ltd.

Yogesh M. Agrawal
Managing Director

Mumbai, 30 January 2019